Dicerna Pharmaceuticals, a drug development company, has made a second closing of its series B round at $4m with SR One, the corporate venturing division of GlaxoSmithKline, joining as a new investor.
Dicerna previously raised $25m in its B round from venture capital firms Oxford Bioscience Partners, Skyline Ventures, Abingworth and Domain Associates, all of which participated in this round.
Brian Gallagher, a partner at SR One, which has invested about $600m in more than 130 companies since 1985, will become an observer on Dicerna’s board.
Doug Fambrough, chief executive of Dicerna, said: "Following our first close of the series B in August, we re-opened the round due to significant additional interest from the investment community in our unique Dicer Substrate Technology platform [pictured] and next generation approach to developing RNAi therapeutics."
Gallagher said: "Dicerna squarely met our strategic investment criteria, as SR One seeks to invest in early stage companies pursuing innovative approaches to developing breakthrough science."
Since its launch in 2007, Dicerna has raised about $50m.